Cover Image
市場調查報告書

遊離脂肪酸受體1(G蛋白質共軛型受體40/FFAR1):開發平台分析

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 358349
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
遊離脂肪酸受體1(G蛋白質共軛型受體40/FFAR1):開發平台分析 Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 52 Pages
簡介

遊離脂肪酸受體1(FFAR1)同時也稱作G蛋白質共軛型受體40,是藉由FFAR1遺傳基因編碼化的A級G蛋白質結合受體。雖然在胰島細胞非常容易發現,但腦內則相當稀少。這個膜蛋白質結合遊離脂肪酸,可調節營養中樞能量平衡。

本報告提供全球各國遊離脂肪酸受體1開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

研究中的產品的一覽(大學/研究機關別)

治療藥的評估

  • 單劑/併用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Amgen Inc.
  • Advinus Therapeutics Ltd.
  • Astellas Pharma Inc.
  • Caldan Therapeutics Limited
  • Connexios Life Sciences Pvt. Ltd.
  • 第一三共
  • Hyundai Pharmaceutical Co., Ltd.
  • 日本煙草產業
  • Jiangsu Hengrui Medicine Co., Ltd.

藥物簡介

  • AM-1638
  • AM-3189
  • AM-6226
  • AS-2034178
  • AS-2575959
  • CNX-011-67
  • DS-1558
  • HD-6277
  • JTT-851
  • 第二型糖尿病GPR40/GPR120受體激動劑
  • 第二型糖尿病GPR40促效劑
  • 肥胖GPR40拮抗劑
  • 糖尿病GPR40促效劑
  • TUG-770

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0516TDB

Summary

Global Markets Direct's, 'Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2016', provides in depth analysis on Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted pipeline therapeutics.

The report provides comprehensive information on the Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)
  • The report reviews Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Overview
  • Therapeutics Development
    • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Products under Development by Stage of Development
    • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Products under Development by Therapy Area
    • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Products under Development by Indication
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Products under Development by Companies
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Products under Development by Universities/Institutes
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Companies Involved in Therapeutics Development
    • Advinus Therapeutics Ltd
    • Amgen Inc.
    • Astellas Pharma Inc.
    • Caldan Therapeutics Limited
    • Connexios Life Sciences Pvt. Ltd.
    • Daiichi Sankyo Company, Limited
    • Hyundai Pharmaceutical Co., Ltd.
    • Japan Tobacco Inc.
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Merck & Co., Inc.
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Drug Profiles
    • AM-1638 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-3189 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-6226 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AS-2034178 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AS-2575959 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CNX-01167 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-1558 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HD-6277 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JTT-851 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-8666 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize GPR40 and GPR120 Receptors for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize GPR40 for Obesity - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize GPR40 for Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TUG-770 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Dormant Projects
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Discontinued Products
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Featured News & Press Releases
    • Apr 10, 2012: Connexios in discussions to partner early-stage GPR40 diabetes drug, CRO will be chosen in US/EU -CEO
    • Jun 27, 2011: Connexios Life Science Presents Preclinical Data On CNX-011-67 At American Diabetes Association Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Advinus Therapeutics Ltd, H2 2016
  • Pipeline by Amgen Inc., H2 2016
  • Pipeline by Astellas Pharma Inc., H2 2016
  • Pipeline by Caldan Therapeutics Limited, H2 2016
  • Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016
  • Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
  • Pipeline by Japan Tobacco Inc., H2 2016
  • Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
  • Pipeline by Merck & Co., Inc., H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top